Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Allison M Deal, Mark G Kris, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 23, 2013
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Jennifer L Hay, Thomas M Atkinson, Bryce B Reeve, et al.JMIR Human Factors|July 18, 2018
Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability StudyMartin W Schoen, Ethan Basch, Lori L Hudson, et al.Translational Behavioral Medicine|September 28, 2013
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Deborah Watkins Bruner, Laura J Hanisch, Bryce B Reeve, et al.Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.Journal of the National Cancer Institute|October 1, 2014
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)Ethan Basch, Bryce B Reeve, Sandra A Mitchell, et al.Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.Pageof 2